ESALF News and Press, Eisai Co Ltd From 11/07/22

Eisai Co., Ltd. (ESALF) Q2 2022 Earnings Conference Call November 7, 2022 02:00 ET Company Participants Haruo Naito - Representative Corporate Officer and Chief Executive Officer Ivan Cheung - Senior Vice President, Global Alzheimer's Disease Officer, President, Amer...

Call Start: 02:00 Call End: 03:28 Eisai Co., Ltd. (ESALF) Q2 2023 Earnings Conference Call November 7, 2022 02:00 ET Company Participants Haruo Naito - Representative Corporate Officer and Chief Executive Officer Ivan Cheung - Senior Vice President, Global Al...

Summary Biogen appears set to obtain approval of a 2nd Alzheimer's drug. Lecanemab is far better received by the market with total peak sales forecasted at up to $14 billion with Biogen sharing 50% of the profits. The earnings potential of the Alzheimer's franchise places the ...

Summary Biogen remains a financially cheap, unloved Big Pharma name with a number of promising drugs under development. The latest positive readout on LECANEMAB, its second Alzheimer's drug likely to get FDA approval, could increase EPS dramatically in future years. Strong ups...

Summary Alzheimer's Disease is one of the largest unmet medical needs. Today, there are 139 drugs in clinical trials for Alzheimer's. In this piece, we dive into 8 of the most impactful and promising trials. Introduction Alzheimer's disease is the largest unmet...

Summary Non-APOE4 carriers do not benefit from treatment with lecanemab. Lecanemab reduces the rate of progression of APOE4 carriers closer to that of non-carriers in mild Alzheimer's disease. While rare, brain swelling and brain bleeds may occur in APOE4 carriers on lecanemab...

Summary Eisai and Biogen get another chance. Still not a cure, but a big step forward even though it's still just a glimmer of hope for Alzheimer’s sufferers. The big news is that lecanemab produced a measurable effect for slowing early Alzheimer’s. The question ...

Summary The big news last night was the announcement of a positive readout in Eisai and Biogen's trial of lecanemab, another attempt at an anti-amyloid antibody for Alzheimer's therapy. As the world knows, the anti-amyloid clinical landscape for Alzheimer's is absolutely littered ...

Summary Q2 results are on the table and Idorsia could convince with encouraging developments in its pipeline and its initial commercial efforts with QUVIVIQ (Daridorexant) and PIVLAZ (Clazosentan). The Swiss and Canadian health authorities are supposed to give their feedback on QU...

There is a critical upcoming catalyst for Biogen shareholders, a topline read out of data from the CLARITY-AD trial in Alzheimer’s due in late September. One lesson from the Aduhelm fiasco is that data that clearly shows patients benefit from treatment is required for commercia...